Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Molecular Imaging and Biology
Erschienen in:

10.01.2022 | Research Article

Synthesis and Evaluation of Radioiodine-Labeled pH (Low) Insertion Peptide Variant 7-Like Peptide as a Noninvasive Tumor Microenvironment Imaging Agent in a Mouse MDA-MB-231 Triple-Negative Breast Cancer Model

verfasst von: FengYu Wu, YueHua Chen, DaCheng Li, ZhenGuang Wang, MingMing Yu

Erschienen in: Molecular Imaging and Biology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The pH (low) insertion peptide (pHLIP) family can target the tumor microenvironment (TME). If pHLIP can be labeled with radioiodine, the imaging and treatment of tumors can be considered. However, tyrosine and tryptophan can bind with iodine in the insertion region of pHLIP, and radioiodine labeling may affect the formation of α-helix structures in acidic environments; therefore, it is necessary to adjust the structure of pHLIP. This study aims to develop an 125I-labeled pH (low) insertion peptide variant 7-like peptide (pHLIP (Var7) LP) for imaging the TME in MDA-MB-231 triple-negative breast cancer (TNBC) xenograft tumor models.

Procedures

Based on pHLIP (Var7), a new peptide sequence, pHLIP (Var7) LP, was obtained by the sequence modification method and then characterized. The binding of pHLIP (Var7) LP to MDA-MB-231 cells was analyzed. pHLIP (Var7) LP was labeled with 125I by the iodogen iodination method. Serial biodistribution studies and small-animal single photon emission computed tomography (SPECT)/computed tomography (CT) imaging in subcutaneous MDA-MB-231 TNBC-bearing mice were performed using [125I] I-pHLIP (Var7) LP.

Results

A novel peptide, pHLIP (Var7) LP, has the characteristics of an α-helix structure, electronegativity, and amphiphilicity. Circular dichroism (CD) spectroscopy showed that the peptide presented a typical pH-dependent transition from an unstructured conformation to an α-helix structure when the pH was reduced from 8.0 to 4.0. The relative fluorescence intensities of 5-carboxytetramethylrhodamine (5-TAMRA)-pHLIP(var7) LP at pH = 6.0, 6.6, and 7.4 were 100.00 ± 5.98%, 72.10 ± 4.65%, and 13.72 ± 1.41%, respectively. The distribution of [125I] I-pHLIP (Var7) LP in tumors reached the highest level (8.7 ± 1.6% ID/g) at 2 h after injection, and the tumor-to-muscle ratios and tumor-to-blood ratios increased with time. Of the measured off-target organs, the stomach, kidney, and bladder showed higher uptake levels. SPECT imaging revealed rapid and sustained tumor uptake of [125I] I-pHLIP (Var7) LP in breast cancer-bearing mice.

Conclusions

This study showed that [125I]I-pHLIP (Var7)LP had rapid and sustained tumor uptake in MDA-MB-231 TNBC and provided a new method for TNBC imaging and further treatment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Pareja F, Reis-Filho JS (2018) Triple-negative breast cancers—a panoply of cancer types. Nat Rev Clin Oncol 15(6):347–348CrossRef
2.
Penault-Llorca F, Viale G (2012) Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Ann Oncol 23(Suppl 6):vi19-22CrossRef
3.
Aebi S, Davidson T, Gruber G et al (2011) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi12-24CrossRef
4.
Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938–1948CrossRef
5.
Jitariu AA, Cîmpean AM, Ribatti D et al (2017) Triple negative breast cancer: the kiss of death. Oncotarget 8(28):46652–46662CrossRef
6.
Ditsch N, Kolberg-Liedtke C, Friedrich M et al (2021) AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. Breast Care (Basel) 16(3):214–227CrossRef
7.
Bakker MF, de Lange SV, Pijnappel RM et al (2019) Supplemental MRI screening for women with extremely dense breast tissue. N Engl J Med 381(22):2091–2102CrossRef
8.
Elghazaly H, Rugo HS, Azim HA et al (2021) Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. Cancers (Basel) 13(9):2262CrossRef
9.
Beusterien K, Grinspan J, Kuchuk I et al (2014) Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects. Oncologist 19(2):127–134CrossRef
10.
Liu Z, Jiang L, Liang G et al (2017) Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: a review and meta-analysis of prophylaxis management. J Viral Hepat 24(7):561–572CrossRef
11.
Cairns R, Papandreou I, Denko N (2006) Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 4(2):61–70CrossRef
12.
Pathak AP, Gimi B, Glunde K et al (2004) Molecular and functional imaging of cancer: advances in MRI and MRS. Methods Enzymol 386:3–60PubMed
13.
Penet MF, Glunde K, Jacobs MA et al (2008) Molecular and functional MRI of the tumor microenvironment. J Nucl Med 49(5):687–690CrossRef
14.
Yu M, Chen Y, Wang Z et al (2020) pHLIP (Var7)-P1AP suppresses tumor cell proliferation in MDA-MB-231 triple-negative breast cancer by targeting protease activated receptor 1. Breast Cancer Res Treat 180(2):379–384CrossRef
15.
Chen YH, Yu MM, Wang ZG (2021) Inhibition of MDA-MB-231 cell proliferation by pHLIP (Var7)-P1AP and SPECT imaging of MDA-MB-231 breast cancer-bearing nude mice using 125I-pHLIP (Var7)-P1AP. Nuklearmedizin 60(3):240–248CrossRef
16.
Yu M, Sun Y, Yang G et al (2021) An experimental study on [125I]I-pHLIP (Var7) for SPECT/CT imaging of an MDA-MB-231 triple-negative breast cancer mouse model by targeting the tumor microenvironment. Mol Imaging 2021:5565932CrossRef
17.
Tossi A, Sandri L, Giangaspero A (2000) Amphipathic, alpha-helical antimicrobial peptides. Biopolymers 55(1):4–30CrossRef
18.
Demoin DW, Wyatt LC, Edwards KJ et al (2016) PET imaging of extracellular pH in tumors with (64) Cu- and (18)F-labeled pHLIP peptides: a structure-activity optimization study. Bioconjug Chem 27(9):2014–2023CrossRef
19.
Sosunov EA, Anyukhovsky EP, Sosunov AA et al (2013) pH (low) insertion peptide (pHLIP) targets ischemic myocardium. Proc Natl Acad Sci U S A 110(1):82–86CrossRef
20.
Yu M, Zhou H, Liu X et al (2010) Study on biodistribution and imaging of radioiodinated arginine-arginine-leucine peptide in nude mice bearing human prostate carcinoma. Ann Nucl Med 24(1):13–19CrossRef
21.
MingMing Yu, Wang RongFu, Yan P et al (2008) Design, synthesis and iodination of an Arg-Arg-Leu peptide for potential use as an imaging agent for human prostate carcinoma. J Label Compd Radiopharm 51(11):374–378CrossRef
22.
Josefsson M, Grunditz T, Ohlsson T et al (2002) Sodium/iodide-symporter: distribution in different mammals and role in entero-thyroid circulation of iodide. Acta Physiol Scand 175(2):129–137CrossRef
23.
Andreev OA, Dupuy AD, Segala M et al (2007) Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo. Proc Natl Acad Sci U S A 104(19):7893–7898CrossRef
24.
Macholl S, Morrison MS, Iveson P et al (2012) In vivo pH imaging with (99m)Tc-pHLIP. Mol Imaging Biol 14(6):725–734CrossRef
25.
Daumar P, Wanger-Baumann CA, Pillarsetty N et al (2012) Efficient (18)F-labeling of large 37-amino-acid pHLIP peptide analogues and their biological evaluation. Bioconjug Chem 23(8):1557–1566CrossRef
Metadaten
Titel
Synthesis and Evaluation of Radioiodine-Labeled pH (Low) Insertion Peptide Variant 7-Like Peptide as a Noninvasive Tumor Microenvironment Imaging Agent in a Mouse MDA-MB-231 Triple-Negative Breast Cancer Model
verfasst von
FengYu Wu
YueHua Chen
DaCheng Li
ZhenGuang Wang
MingMing Yu
Publikationsdatum
10.01.2022
Verlag
Springer International Publishing
Erschienen in
Molecular Imaging and Biology / Ausgabe 4/2022
Print ISSN: 1536-1632
Elektronische ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-021-01702-0

Weitere Artikel der Ausgabe 4/2022

Evaluation of [18F]F-DPA PET for Detecting Microglial Activation in the Spinal Cord of a Rat Model of Neuropathic Pain

  • Open Access
  • Research Article

Heterodimeric RGD-NGR PET Tracer for the Early Detection of Pancreatic Cancer

  • Research Article

Head-to-head Intra-individual Comparison of [68Ga]-FAPI and [18F]-FDG PET/CT in Patients with Bladder Cancer

  • Open Access
  • Research Article

EGFR-Targeted ImmunoPET of UMUC3 Orthotopic Bladder Tumors

  • Brief Article

Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers

  • Open Access
  • Research Article

Intratumoral and Peritumoral Analysis of Mammography, Tomosynthesis, and Multiparametric MRI for Predicting Ki-67 Level in Breast Cancer: a Radiomics-Based Study

  • Research Article

Neu im Fachgebiet Radiologie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Stumme Schlaganfälle − ein häufiger Nebenbefund im Kopf-CT?

In 4% der in der Notfallambulanz initiierten zerebralen Bildgebung sind „alte“ Schlaganfälle zu erkennen. Gar nicht so selten handelt es sich laut einer aktuellen Studie dabei um unbemerkte Insulte. Bietet sich hier womöglich die Chance auf ein effektives opportunistisches Screening?

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Stören weiße Wände und viel Licht die Bildqualitätskontrolle?

Wenn es darum geht, die technische Qualität eines Mammogramms zu beurteilen, könnten graue Wandfarbe und reduzierte Beleuchtung im Bildgebungsraum von Vorteil sein. Darauf deuten zumindest Ergebnisse einer kleinen Studie hin. 

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise